When grouped according to the median value of serum IL-17A (0.1 pg/ml), the results showed that MM patients with IL-17A > 0.1 pg/ml had more severe bone lesions than MM patients with IL-17A ≤ 0.1 pg/ml (β = 1.60; 95% CI (1.06, 2.13); p < 0.0001) and a higher incidence of fracture (OR = 6.77; 95% CI (2.61, 17.55); p < 0.0001) among the participants (Table 2). This evidence concerns the gene IL17A and Miyoshi myopathy.